本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 3 月 13 日 证券代码：688687 证券简称：凯因科技 公告编号：2026-009 北京凯因科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二） 股东会召开的地点：北京市北京经济技术开发区荣京东街 6 号 3 号楼会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 127 | | --- | --- | | 普通股股东人数 | 127 | | 2、出席会议的股东所持有的表决权数量 | 43,900,287 | | 普通股股东所持有表决权数量 | 43,900,287 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 25.6810 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 25.6810 | （ ...

广东信达律师事务所（以下简称"信达"）接受北京凯因科技股份有限公司 （下称"贵公司"）的委托，指派律师参加了贵公司 2026 年第一次临时股东会 （下称"本次股东会"），并进行了必要的验证工作。 广东信达律师事务所 股东会法律意见书 深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 11/12/F, Tai Ping Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 83265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www.sundiallawfirm.com 广东信达律师事务所 关于北京凯因科技股份有限公司 2026 年第一次临时股东会的 法律意见书 信达科会字[2026]第 011 号 致：北京凯因科技股份有限公司 信达律师根据《中华人民共和国公司法》（下称"《公司法》"）、《上市 公司股东会规则》（下称"《股东会规则》"）等法律、法规 ...

证券代码：688687 证券简称：凯因科技 公告编号：2026-008 北京凯因科技股份有限公司 控股股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 控股股东持有的基本情况 截至本公告披露日，北京凯因科技股份有限公司（以下简称"公司"）控股 股东北京松安投资管理有限公司（以下简称"松安投资"）直接持有公司股份 38,400,000 股，占公司总股本的 22.46%，股份来源于公司首次公开发行股票并 上市前所取得的股份，且已于 2024 年 2 月 8 日全部解除限售并上市流通。 减持计划的主要内容 因松安投资股东北京智达宇恒经济发展咨询有限公司及向慧川自身资金需 求，松安投资拟通过集中竞价、大宗交易方式减持其所持有的公司股份合计不超 过 3,420,000 股，占公司总股本的 2.0007%。其中通过集中竞价交易方式减持不 超过 1,709,444 股，即不超过公司总股本的 1.00%；通过大宗交易方式减持不超 过 3,418,888 股，即不超过公司总股本的 2.00%， ...

北京凯因科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2026 年第一次临时股东会 会议资料 二○二六年三月 1 北京凯因科技股份有限公司 2026 年第一次临时股东会会议资料 目 录 | 2026 年第一次临时股东会会议须知 | 3 | | --- | --- | | 2026 年第一次临时股东会会议议程 | 5 | | 议案一：关于补选独立董事及调整董事会专门委员会委员的议案 | 7 | 2 四、开会期间参会人员应注意维护会场秩序，不要随意走动，手机调整为静 音状态，谢绝个人录音、录像及拍照，对干扰会议正常程序、寻衅滋事或侵犯其 他股东合法权益的行为，会议工作人员有权予以制止，并报告有关部门处理。 五、股东及股东代理人依法享有发言权、质询权、表决权等权利。股东及股 东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其他股东及股东代 理人的合法权益，不得扰乱股东会的正常秩序。 六、要求发言的股东及股东代理人，应当按照会议的议程，经会议主持人许 可方可发言。有多名股东及股东代理人同时要求发言时，先举手者发言；不能确 定先后时， ...

Core Viewpoint - The company reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.35%. However, the net profit attributable to the parent company was 29.6312 million yuan, showing a significant decline of 79.19% compared to the previous year due to substantial asset impairment provisions [1]. Financial Performance - Total operating revenue reached 1.321 billion yuan, marking a 7.35% increase year-on-year [1]. - Net profit attributable to the parent company was 29.6312 million yuan, which represents a 79.19% decrease year-on-year [1]. Reasons for Performance Changes - The primary reason for the performance decline was the company's decision to make a large asset impairment provision. This was influenced by the latest review recommendations from the National Medical Products Administration [1]. - The company voluntarily withdrew the drug registration application for the interferon α-2 injection (new hepatitis B indication), leading to a full impairment provision for the remaining development expenses of this project [1].

Core Viewpoint - Kaiyin Technology (688687.SH) reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.35%. However, the net profit attributable to the parent company was 29.6312 million yuan, showing a significant decline of 79.19% due to substantial asset impairment provisions [1] Financial Performance - The company achieved total operating revenue of 1.321 billion yuan, which is a 7.35% increase compared to the previous year [1] - The net profit attributable to the parent company was 29.6312 million yuan, representing a 79.19% decrease year-on-year [1] Reasons for Performance Changes - The primary reason for the decline in net profit is the company's decision to make a large asset impairment provision [1] - The company voluntarily withdrew its drug registration application for the new hepatitis B indication of Pegylated Interferon α-2 Injection based on the latest review recommendations from the National Medical Products Administration, leading to a full impairment of the remaining development expenses for this project [1]

Core Viewpoint - Kaiyin Technology (688687.SH) reported a significant decline in net profit for the year 2025, primarily due to substantial asset impairment provisions related to the withdrawal of a drug registration application [1] Financial Performance - The company achieved total operating revenue of 1.321 billion yuan, representing a year-on-year increase of 7.35% [1] - The net profit attributable to the parent company was 29.6312 million yuan, reflecting a year-on-year decrease of 79.19% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 22.7647 million yuan, down 83.38% year-on-year [1] Reasons for Performance Changes - The primary reason for the performance decline was the company's decision to fully provision for asset impairment related to the withdrawal of the drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) based on the latest review recommendations from the National Medical Products Administration [1]

Core Viewpoint - Kaiyin Technology announced that it expects to achieve total operating revenue of 1,320.78 million yuan in 2025, representing a year-on-year growth of 7.35% and a net profit attributable to the parent company of 29.63 million yuan [2] Financial Performance - The projected total operating revenue for 2025 is 1,320.78 million yuan [2] - The expected year-on-year growth rate for revenue is 7.35% [2] - The net profit attributable to the parent company is forecasted to be 29.63 million yuan [2]

Revenue and Profit - Total revenue for 2025 reached RMB 132,078.27 million, representing a year-on-year increase of 7.35%[3] - Net profit attributable to shareholders of the parent company was RMB 2,963.12 million, a decrease of 79.19% compared to the previous year[3] - The company recorded a significant decline in operating profit, down 67.24% year-on-year, totaling RMB 6,323.57 million[3] - The net profit after deducting non-recurring gains and losses was RMB 2,276.47 million, down 83.38% year-on-year[3] - Basic earnings per share fell to RMB 0.17, down 80.00% from RMB 0.85 in the previous year[3] - The company attributed the significant decline in profits to a large asset impairment provision related to the withdrawal of a drug registration application[5] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 279,463.78 million, reflecting a growth of 6.84% year-on-year[3] - The equity attributable to shareholders of the parent company decreased by 6.16% to RMB 172,975.34 million[3] Financial Metrics - The weighted average return on net assets decreased by 6.27 percentage points to 1.66%[3] - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[6]

Group 1 - The company reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, representing a year-on-year increase of 7.35% [1] - The net profit for the same period was 29.6312 million yuan, showing a significant year-on-year decline of 79.19% [1] - The company made a substantial asset impairment provision during the reporting period [1] Group 2 - The company decided to voluntarily withdraw the drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) based on the latest review suggestions from the National Medical Products Administration [1] - As a result of this decision, the company fully provided for the asset impairment related to the remaining development expenses of this project [1]